Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis.
Tasset I, Bahamonde C, Agüera E, Conde C, Cruz AH, Pérez-Herrera A, Gascón F, Giraldo AI, Ruiz MC, Lillo R, Sánchez-López F, Túnez I.
Tasset I, et al. Among authors: tunez i.
Pharmacol Rep. 2013;65(3):624-31. doi: 10.1016/s1734-1140(13)71039-9.
Pharmacol Rep. 2013.
PMID: 23950585
Free article.